
June 10 (Reuters) - Philogen SpA PHIL.MI:
PHILOCHEM AG ANNOUNCES THE LICENSING OF WORLDWIDE RIGHTS TO ONCOACP3, A NOVEL RADIOPHARMACEUTICAL THERAPEUTIC AND DIAGNOSTIC AGENT TARGETING PROSTATE CANCER, TO RAYZEBIO, A BRISTOL-MYERS SQUIBB COMPANY, FOR A POTENTIAL VALUE OF UP TO $1.35BN PLUS ROYALTIES
PHILOGEN SPA - CONSIDERATION COMPOSED OF A $350M UP-FRONT PAYMENT
PHILOGEN SPA- CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES PAYABLE ON GLOBAL NET SALES OF THERAPEUTIC AND DIAGNOSTIC AGENTS OF ONCOACP3
PHILOGEN SPA - CONSIDERATION COMPOSED OF UP TO $1.0BN IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES